THE VACCINIA ENHANCED TEMPLATE (VET™) BACKBONE

KALIVIR‘s VET™ backbone uniquely enhances systemic delivery of the virus to cancer cells by using B cells as IV delivery vehicles.

One key component of the VET™ backbone is the expression of various chemokine receptors from vaccinia virus. Our chemokine receptor expressing vaccinia virus is able to infect B cells in circulation, and drive the infected B cells to traffic towards tumors that express matching chemokines instead of lymph nodes. Vaccinia virus in the infected B cells is protected from circulating antibodies, and therefore is able to reach the tumor safely via systemic delivery.

This unique mechanism greatly enhances the IV delivery capability of our oncolytic vaccinia viruses. It allows VET™ viruses to target a wide array of different types of cancer that normally could not be addressed via intratumoral injection.